Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03494998 | Refining and Testing the Diagnostic Accuracy of PAT-POPS | unknown | — | 80,000 | Pennine Acute Hospitals NHS TrustOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT03488160 | CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma | unknown | N/A | 6 | Sinobioway Cell Therapy Co., Ltd.INDUSTRY | 1 | Apr 10, 2018 | clinicaltrials |
| NCT02955810 | Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)(CyBorD-Dara) | unknown | Phase 1 | 18 | National University of Ireland, Galway, IrelandOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT03479918 | R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS) | unknown | Phase 3 | 80 | Elena N.ParovichnikovaNETWORK | 1 | Mar 27, 2018 | clinicaltrials |
| NCT03475628 | Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma(REBUILD) | unknown | Phase 2 | 57 | Hellenic Society of HematologyOTHER | 1 | Mar 23, 2018 | clinicaltrials |
| NCT01862445 | Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients | unknown | — | 100 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02744768 | D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia | unknown | Phase 2 | 60 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT03468153 | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma | unknown | Phase 1 / Phase 2 | 10 | Ruijin HospitalOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT01719835 | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study(CHEMO-T) | unknown | Phase 2 | 87 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT02280993 | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients | unknown | Phase 1 | 72 | Marjolein SpieringOTHER | 4 | Mar 13, 2018 | clinicaltrials |
| NCT03462095 | De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL) | unknown | N/A | 350 | National Research Center for Hematology, RussiaNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03463928 | A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia | unknown | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03456466 | Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 122 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 7, 2018 | clinicaltrials |
| NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT02354313 | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients(MCL0208) | unknown | Phase 3 | 300 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Feb 9, 2018 | clinicaltrials |
| NCT03417414 | Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases? | unknown | — | 160 | Ottawa Hospital Research InstituteOTHER | 0 | Feb 7, 2018 | clinicaltrials |
| NCT03419494 | Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients | unknown | — | 40 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03413046 | The Effect of Chemotherapy on Regulatory T Cells | unknown | — | 60 | Ankara Children's Health and Diseases Hematology and Oncology Training and Research HospitalOTHER_GOV | 0 | Jan 29, 2018 | clinicaltrials |
| NCT03221348 | A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma | unknown | Phase 1 | 24 | Cho Pharma Inc.INDUSTRY | 0 | Jan 24, 2018 | clinicaltrials |
| NCT03398967 | A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT03392714 | Bendamustine-based Combination Therapy for PCNSL | unknown | Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT03391726 | CART-19 Cells for R/R B-cell Lymphoma(CCFRRBL) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT03391739 | CART-19 Cells For R/R B-ALL(CCFRRBA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02560441 | Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type | unknown | Phase 2 | — | Chinese Academy of Medical SciencesOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT02924753 | The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 1 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03322735 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03383952 | A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia | unknown | Phase 1 | 20 | Immune Cell, Inc.INDUSTRY | 1 | Dec 27, 2017 | clinicaltrials |
| NCT03383965 | CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas | unknown | Phase 1 | 20 | Immune Cell, Inc.INDUSTRY | 1 | Dec 27, 2017 | clinicaltrials |
| NCT03383406 | A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma(IVAM) | unknown | Phase 2 | 30 | Asan Medical CenterOTHER | 0 | Dec 26, 2017 | clinicaltrials |
| NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | unknown | Phase 3 | 870 | Prof. Dr. M. Dreyling (co-chairman)OTHER | 5 | Dec 19, 2017 | clinicaltrials |
| NCT03299738 | A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL | unknown | Phase 1 | 10 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03373526 | Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation | unknown | N/A | 50 | Daniel Godoy MartinezOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03373019 | Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | unknown | Phase 2 | 63 | Fudan UniversityOTHER | 1 | Dec 14, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01746992 | CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma | unknown | Phase 4 | 200 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01852435 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | unknown | Phase 3 | 648 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02542111 | A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL | unknown | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02753543 | Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma | unknown | Phase 2 | 33 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02753647 | Chidamide Plus R-CHOP in Elderly DLBCL | unknown | Phase 2 | 49 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03340155 | Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases(BioUV2017) | unknown | N/A | 240 | Medical University of GrazOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT03154918 | GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma | unknown | Phase 2 | 60 | Sichuan UniversityOTHER | 1 | Nov 8, 2017 | clinicaltrials |
| NCT03335098 | Study of VTD in Waldenstrom's Macroglobulinemia(BOMB-THROW) | unknown | Phase 2 | 15 | Seoul National University HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT03321890 | Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | unknown | Phase 2 | 102 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01329354 | Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy | unknown | Phase 2 | 38 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT03263208 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 / Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 20, 2017 | clinicaltrials |
| NCT02488382 | Lonquek for Autologous Stem Cell Mobilization | unknown | Phase 1 / Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Oct 17, 2017 | clinicaltrials |
| NCT03229616 | BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02885623 | Role of CX3CR1-expressing Cells in Hematologic Malignancy | unknown | — | 50 | Saint Vincent's Hospital, KoreaOTHER | 1 | Oct 11, 2017 | clinicaltrials |
| NCT03298828 | CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | unknown | Phase 1 | 30 | Third Military Medical UniversityOTHER | 0 | Oct 2, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Apr 11, 2018source: clinicaltrials